Oxford Biomedica Solutions
Samantha Knott is a seasoned professional in quality control and method monitoring, currently serving as Manager of Method Monitoring & Critical Reagents at bluebird bio since August 2023. Previous roles include Senior Method Monitoring & Critical Reagent Analyst at 2seventy bio and Method Monitoring & Critical Reagent Analyst at bluebird bio, where responsibilities encompassed the procurement and management of critical reagents, statistical analyses, and internal policy documentation. Samantha has experience in quality control microbiology from Adaptimmune and has a strong educational background with a Master of Science in Microbiology and Immunology from Thomas Jefferson University and a Bachelor's degree in Microbiology from the University of the Sciences in Philadelphia.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.